추체 성형술 또는 경피적 풍선 척추 성형술을 시행한 골다공증성 척추 압박 골절 환자에서 알렌드로네이트와 랄록시펜 약물치료 후 발생하는 추가 골절의 비교 연구
Comparison of New Fractures after Treatment with Alendronate or Raloxifene in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds: The purpose of this study was to examine the incidence of new fractures after treatment with alendronate or raloxifene in patients with compression fractures treated with cement augmentation. Methods: 140 patients with compression fracture treated with vertebroplasty or kyphoplasty between January 2007 and January 2013 were divided into 3 groups, an unmedicated group (n=31), an alendronate group (n=49), and a raloxifene group (n=60). The incidence of new fractures in 3 groups were investigated. Results: The incidence of new fractures was 29% (9 cases) in unmedicated group, 20% (10 case) in alendronate group, and 26% (16 case) in raloxifene group. Average period to new fracture was 16.2 months in alendronate group and 21.5 months in raloxifene group. Conclusions: After treatment with alendronate or raloxifene, BMD increased and incidence of new fractures decreased in patients with osteoporotic compression fracture treated with vertebroplasty or kyphoplasty. Patients with alendronate showed numerical improvement in BMD and incidence of new fractures than raloxifene. But, incidence of new fractures in spine and other site showed no statisically significant.
Abstract
Backgrounds: The purpose of this study was to examine the incidence of new fractures after treatment with alendronate or raloxifene in patients with compression fractures treated with cement augmentation. Methods: 140 patients with compression fracture treated with vertebroplasty or kyphoplasty between January 2007 and January 2013 were divided into 3 groups, an unmedicated group (n=31), an alendronate group (n=49), and a raloxifene group (n=60). The incidence of new fractures in 3 groups were investigated. Results: The incidence of new fractures was 29% (9 cases) in unmedicated group, 20% (10 case) in alendronate group, and 26% (16 case) in raloxifene group. Average period to new fracture was 16.2 months in alendronate group and 21.5 months in raloxifene group. Conclusions: After treatment with alendronate or raloxifene, BMD increased and incidence of new fractures decreased in patients with osteoporotic compression fracture treated with vertebroplasty or kyphoplasty. Patients with alendronate showed numerical improvement in BMD and incidence of new fractures than raloxifene. But, incidence of new fractures in spine and other site showed no statisically significant.
참고문헌 (23)
- Kanis JA., "Osteoporosis and osteopenia", J Bone Miner Res, 5, pp.209~211 (1990)
- Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
- Marshall D, "Meta-analysis of how well measure on bone mineral density predict occurrence of osteoporotic fractures", BMJ, 312, pp.1254~1259 (1996)
- Al-Azzawi F, "Long term effect of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry", Br Med J (Clin Res Ed), 294, pp.1261~1262 (1987)
- Lufkin EG, "Treatment of postmenopausal osteoporosis with transdermal estrogen", Ann Intern Med, 117, pp.1~9 (1992)
- Overgaard K, "Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis:a dose-response study", BMJ, 305, pp.556~561 (1992)
- Pak CY, "Treatment of postmenopausal osteoporosis with slow release sodium fluoride: final report of a randomized controlled trial", Ann Intern Med, 123, pp.401~408 (1995)
- Riggs BL, "Effect of the fluoride", calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis, 1982, pp.306, 446~450
- Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis", N Engl J Med, 333, pp.1437~1443 (1995)
- Storm T, "Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis", N Engl J Med, 322, pp.1265~1271 (1990)
- Watts NB, "Intermittent cyclical etidronate treatment of postmenopausal osteoporosis", N Engl J Med, 323, pp.73~79 (1990)
- Carano A, "Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro", J Clin Invest, 85, pp.456~461 (1990)
- Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", JAMA, 282, pp.637~645 (1999)
- Delmas PD, "Eastell R. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis:four-year results from a randomized clinical trial", J Clin Endocrinol Metab, 87, pp.3609~3617 (2002)
- Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
- Tilyard MW, "Treatment of postmenopausal osteoporosis with cal citriol or calcium", N Engl J Med, 326, pp.357~362 (1992)
- Rabenda V, "Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women", Osteoporos Int, 19, pp.811~818 (2008)
- Devogelaer JP, "Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis", Bone, 18, pp.141~150 (1996)
- Ravn P, "Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group", J Clin Endocrinol Metab, 85, pp.1492~1497 (2000)
- Black DM, "Randomised trail of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
- Sambrook PN, "Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International", J Intern Med, 255, pp.503~511 (2004)
- Wasnich RD, "Vertebral Fracture epidemiology", Bone, 18, pp.179S~183S (1996)
- Lindsay R, "Risk of new vertebral fracture in the year following a fracture", JAMA, 285, pp.320~323 (2001)